Ensysce Biosciences Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Key Points for Investors

• Ensysce Biosciences, Inc. (Nasdaq: ENSC) has received a notice from The Nasdaq Stock Market regarding non-compliance with the minimum bid price requirement.
• Date of Deficiency Letter: February 25, 2026
• Minimum Bid Price Rule: The company’s common stock has failed to maintain a minimum closing bid price of \$1.00 per share for 30 consecutive business days.
• Compliance Deadline: Ensysce has until August 24, 2026 (180 calendar days) to regain compliance.
• Compliance Criteria: The stock price must close at or above \$1.00 per share for at least ten consecutive business days within this period.
• If compliance is not regained by the deadline, Nasdaq may grant an additional extension if all other listing requirements are met.
• There is no immediate impact on the company’s listing status; shares will continue trading on Nasdaq under the symbol “ENSC”.

Details and Implications for Shareholders

On February 25, 2026, Ensysce Biosciences, Inc. received an official notice (the “Deficiency Letter”) from the listing qualifications department staff of The Nasdaq Stock Market. The letter states that the company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of \$1.00 per share.

According to the Deficiency Letter, Ensysce now has a compliance period of 180 calendar days, expiring on August 24, 2026, to remedy the deficiency. To regain compliance, the company’s common stock must close at or above \$1.00 per share for at least ten consecutive business days during this period. In some cases, Nasdaq may require a longer compliance period, but typically no more than 20 consecutive business days.

If Ensysce does not regain compliance by August 24, 2026, the company may be eligible for an additional 180-day extension if it meets all other Nasdaq initial and continuing listing standards, except for the minimum bid price requirement. However, there is no guarantee that such an extension will be granted.

The company has stated its intention to actively monitor the stock’s closing bid price during the compliance period and to evaluate available options to resolve the deficiency, including potential corporate actions such as a reverse stock split if deemed appropriate.

Importantly, the Deficiency Letter does not have an immediate effect on the listing or trading of Ensysce’s common stock. Shares will continue to trade on the Nasdaq Capital Market under the ticker symbol “ENSC” while the company works to regain compliance.

However, failure to regain compliance could result in the delisting of Ensysce’s common stock from Nasdaq. Delisting could make it more difficult for shareholders to buy or sell the company’s securities, limit the ability to obtain accurate price quotations, and potentially cause a material decline in the share price. It could also impair the company’s ability to raise capital through public markets and deter broker-dealers and institutional investors from participating in the stock.

What Shareholders Should Watch

• Monitor ENSC’s share price for any announcement or action by the company aimed at regaining compliance (such as a reverse stock split).
• Be aware of the August 24, 2026 compliance deadline.
• Understand that failure to meet Nasdaq listing requirements could negatively impact liquidity, valuation, and the ability to raise capital.
• Any substantial company action in response to the deficiency (such as corporate restructuring, financing, or strategic alternatives) could be a significant price catalyst.

Conclusion

The receipt of a Nasdaq deficiency notice is a material event for Ensysce Biosciences and may create short-term volatility in the company’s share price. Investors are advised to closely follow further updates from the company regarding remedial actions and to consider the risks associated with potential delisting in their investment decisions.

View Ensysce Biosciences, Inc. Historical chart here